查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2045939

新抗原標靶治療市場－全球產業規模、佔有率、趨勢、機會與預測：按標靶疾病指標、新抗原類型、免疫療法類型、給藥途徑、地區和競爭格局分類，2021-2031年

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Target Disease Indication, By Neoantigens Type, By Immunotherapy Type, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球新抗原標靶治療市場預計將從 2025 年的 19.9 億美元大幅成長至 2031 年的 32.3 億美元，複合年成長率為 8.41%。

這些免疫療法旨在識別並清除源自DNA突變的腫瘤特異性抗原，從而精準地誘導免疫系統對抗癌細胞。這項市場擴張的根本驅動力在於全球惡性腫瘤發生率的上升，以及臨床上迫切需要能夠最大限度地減少脫靶毒性的治療方法，最終目標是透過提高腫瘤治療的特異性來改善患者的長期存活率。然而，個人化製劑所需的複雜且資本密集生產流程，為這些治療方法的廣泛應用帶來了巨大挑戰。這些物流障礙使得該行業難以滿足近期健康統計數據所顯示的巨大需求。例如，美國癌症協會預測，到2025年，美國將新增約2,041,910例癌症病例。因此，建立擴充性且經濟高效的生產模式仍然是阻礙該領域更廣泛商業性擴張的關鍵挑戰。

市場概覽
預測期 2027-2031
市場規模：2025年 19.9億美元
市場規模：2031年 32.3億美元
複合年成長率：2026-2031年 8.41%
成長最快的細分市場 預製新抗原
最大的市場 北美洲

市場促進因素

生物資訊學與人工智慧的融合是推動市場發展的主要動力，它能夠從海量的次世代定序資料集中精準識別腫瘤特異性突變。這種技術融合使研發人員能夠選擇最具免疫抗原性的新抗原，顯著提高個人化疫苗的臨床療效，使其優於特異性免疫療法。近期積極的臨床試驗結果也支持了該方法的臨床效用。 2024年6月，Moderna公司報告稱，其在臨床實驗抗原療法mRNA-4157與Pembrolizumab聯合使用，與單藥治療相比，可使高危險群黑色素瘤患者的復發或死亡風險降低49%。這證實了基於電腦的預測演算法已發展成為實用的治療工具。同時，策略合作和研發投入的增加正在加速這些治療方法從實驗階段轉化為商業化階段的發展。製藥公司正大力投資mRNA和載體遞送平台，以克服生產瓶頸並支援後期臨床試驗。例如，BioNTech在2024年3月的聲明中表示，預計累計高達26億歐元用於研發，以推進其腫瘤（癌症治療）產品組合的發展。鑑於國際癌症研究機構（IARC）在2024年預測，到2050年全球癌症患者人數將達到3,500萬，這筆資金的流入意義重大。這表明，可擴展的新抗原解決方案的市場規模巨大。

市場挑戰

主要挑戰在於個人化製劑所需的複雜且資本密集生產流程。這阻礙了滿足全球需求所需的規模化生產，並直接限制了全球新抗原標靶治療市場的成長。與「現成」藥物不同，這些個人化免疫療法需要為每位患者制定獨特的生產週期，因此無法實現標準的規模經濟，導致產品成本過高。因此，製造商在擴大產能以跟上惡性腫瘤日益成長的發病率方面面臨嚴峻挑戰，限制了市場滲透率和患者可及性。這些生產障礙的影響在企業從臨床開發過渡到廣泛商業性成功的過程中所面臨的困難中顯而易見。個人化療法生產的極端複雜性造成了瓶頸，導致只有少數治療方法能夠惠及大量患者。近期行業數據也反映了這種規模化挑戰。根據再生醫學聯盟的說法，到 2025 年，全球先進療法領域約 75% 的銷售額將由不到 10 種產品創造，這凸顯了生產限制對個人化癌症治療方法的廣泛商業性擴張構成了重大障礙。

市場趨勢

現成共用新抗原療法的出現是一個重要的趨勢，它解決了個人化生產固有的規模化限制。這些即用型製劑透過靶向特定患者群體中通用的關鍵驅動突變（例如KRAS），省去了個人化疫苗通常所需的漫長生產週期，使患者能夠立即接受治療。這種簡化的模式已經產生了大量的臨床證據，顯示標靶選擇的標準化可以達到與完全個人化治療方法相當的治療效果。例如，2024年12月，Elicio Therapeutics公司報告稱，其現成候選藥物ELI-002在接受手術切除的KRAS突變固態腫瘤患者中實現了16.3個月的中位無復發生存期，這支持了這種共用抗原療法的有效性。同時，臨床開發正從傳統的轉移性疾病挽救治療轉向輔助性治療治療和早期治療。這項策略轉變旨在透過在患者免疫系統最活躍且腫瘤負荷最小時接種新抗原疫苗，顯著提高根除微量殘存疾病和預防復發的可能性。這種方法已在標準治療往往無效的進行性適應症中取得了持續緩解的成果。 BioNTech公司於2024年4月發表的數據證實了這一點，數據顯示，對於胰腺癌切除術後無應答者，術後自體注射塞維美崙可顯著延長中位無復發生存期至13.4個月，而免疫應答者的中位無復發生存期尚未達到。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：新型抗原標靶治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 目標疾病（骨癌、大腸癌、婦科癌症、非小細胞肺癌、腎細胞癌）
    • 新抗原類型（預製新抗原、個人化新抗原）
    • 免疫療法的類型（樹突細胞疫苗、DNA/RNA疫苗、蛋白質/胜肽疫苗、TIL治療方法）
    • 給藥途徑（皮內、靜脈、皮下）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美新型抗原標標靶治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲新型抗原標標靶治療的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區新型抗原標靶治療的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲新型抗原標標靶治療的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲新型抗原標靶治療的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：新型抗原標靶治療的全球市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • BioNtech SE
  • Gritstone Bio, Inc.
  • Genocea Biosciences Inc.
  • Moderna Inc.
  • Agenus Inc.
  • Immatics NV
  • Advaxis Inc
  • Precision Biologics
  • Gilead Sciences, Inc.
  • Cellular Biomedicine Group Inc.
  • Achillies Therapeutics Plc.
  • Merck & Co Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18740

The Global Neoantigen Targeted Therapies Market is projected for substantial growth, anticipating an increase from USD 1.99 Billion in 2025 to USD 3.23 Billion by 2031, at an 8.41% Compound Annual Growth Rate. These immunotherapeutic agents are specifically engineered to identify and eliminate tumor-specific antigens derived from DNA mutations, thereby directing the immune system precisely against cancer cells. The market's expansion is fundamentally driven by the escalating global incidence of malignancies and the urgent clinical necessity for treatment regimens that minimize off-target toxicity, ultimately aiming to enhance long-term survival through heightened specificity in oncology treatment. However, the widespread adoption of these therapies is significantly challenged by the intricate and capital-intensive manufacturing processes required for individual patient formulations. This logistical impediment complicates the industry's capacity to meet the substantial demand indicated by recent health statistics; for instance, the American Cancer Society projected approximately 2,041,910 new cancer cases in the United States for 2025. Therefore, establishing scalable and cost-efficient production models remains a critical obstacle impeding the broader commercial expansion of this sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.99 Billion
Market Size 2031USD 3.23 Billion
CAGR 2026-20318.41%
Fastest Growing SegmentOff-the-Shelf Neoantigens
Largest MarketNorth America

Market Driver

The integration of bioinformatics and artificial intelligence serves as a primary catalyst for the market, enabling the precise identification of tumor-specific mutations from vast next-generation sequencing datasets. This technological convergence empowers developers to select neoantigens with the highest immunogenicity, thereby significantly enhancing the clinical efficacy of personalized vaccines compared to non-specific immunotherapies. The clinical viability of this approach was recently substantiated by positive trial outcomes; Moderna reported in June 2024 that its investigational neoantigen therapy mRNA-4157, when combined with pembrolizumab, reduced the risk of recurrence or death by 49% in high-risk melanoma patients compared to monotherapy, confirming the maturation of computational prediction algorithms into viable therapeutic tools. Simultaneously, the expansion of strategic partnerships and research investments is accelerating the transition of these therapies from experimental stages to commercial pipelines. Pharmaceutical entities are substantially funding mRNA and vector-based delivery platforms to overcome manufacturing bottlenecks and support late-stage trials; BioNTech, for example, projected a research and development spend of up to €2.6 billion for the 2024 financial year to advance its oncology portfolio, as stated in March 2024. This influx of capital is critical, given that the International Agency for Research on Cancer projected in 2024 that the global cancer burden is expected to rise to 35 million new cases by 2050, underscoring the immense addressable market for scalable neoantigen solutions.

Market Challenge

The principal challenging factor is the intricate and capital-intensive manufacturing process necessary for individual patient formulations, which acts as a direct impediment to the growth of the Global Neoantigen Targeted Therapies Market by preventing the scalability essential to meet global demand. Unlike 'off-the-shelf' pharmaceuticals, these personalized immunotherapies necessitate a unique production cycle for every patient, thereby eliminating standard economies of scale and resulting in prohibitively high costs of goods sold. Consequently, manufacturers encounter severe constraints in expanding production capacity to match the rising prevalence of malignancies, which limits both market penetration and patient access. The impact of these manufacturing hurdles is evident in the difficulty companies face when transitioning from clinical development to broad commercial success. The high complexity of producing personalized treatments creates a bottleneck, allowing only a few therapies to reach a substantial volume of patients. This struggle for scalability is reflected in recent industry data: according to the Alliance for Regenerative Medicine, approximately 75 percent of the global revenue in the advanced therapy sector in 2025 was generated by fewer than 10 products, highlighting the significant friction that manufacturing limitations impose on the broader commercial expansion of personalized oncology regimens.

Market Trends

The emergence of off-the-shelf shared neoantigen therapies represents a key trend addressing the critical scalability limits inherent in personalized manufacturing. By targeting common driver mutations, such as KRAS, that appear across specific patient populations, these ready-to-use formulations eliminate the lengthy production cycles typically required for bespoke vaccines, thus enabling immediate patient access. This streamlined model is beginning to generate substantial clinical evidence, proving that standardizing target selection can yield therapeutic benefits comparable to fully individualized regimens; Elicio Therapeutics, for instance, reported in December 2024 that its off-the-shelf candidate ELI-002 achieved a median recurrence-free survival of 16.3 months in patients with resected KRAS-mutant solid tumors, validating the efficacy of this shared-antigen approach. Concurrently, clinical development is pivoting toward adjuvant and early-stage settings, moving beyond the historical reliance on metastatic salvage lines. This strategic shift aims to eradicate minimal residual disease by deploying neoantigen vaccines when the patient's immune system is most robust and the tumor burden is minimal, significantly increasing the likelihood of preventing relapse. This approach is yielding durable remission data in aggressive indications where standard treatments often fail, as demonstrated by BioNTech's April 2024 data, which showed that adjuvant autogene cevumeran in resected pancreatic cancer resulted in a median recurrence-free survival that was not reached in immune responders, significantly outperforming the 13.4 months observed in non-responders.

Key Market Players

  • BioNtech SE
  • Gritstone Bio, Inc.
  • Genocea Biosciences Inc.
  • Moderna Inc.
  • Agenus Inc.
  • Immatics NV
  • Advaxis Inc
  • Precision Biologics
  • Gilead Sciences, Inc.
  • Cellular Biomedicine Group Inc.
  • Achillies Therapeutics Plc.
  • Merck & Co Inc.

Report Scope

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neoantigen Targeted Therapies Market, By Target Disease Indication

  • Bone Cancer
  • Colorectal Cancer
  • Gynecological Cancer
  • Non-Small Cell Lung Cancer
  • Renal Cell Carcinoma

Neoantigen Targeted Therapies Market, By Neoantigens Type

  • Off-the-Shelf Neoantigens
  • Personalized Neoantigens

Neoantigen Targeted Therapies Market, By Immunotherapy Type

  • Dendritic Cell Vaccines
  • DNA / RNA-Based Vaccines
  • Protein / Peptide-based Vaccines
  • TIL-Based Therapies

Neoantigen Targeted Therapies Market, By Route of Administration

  • Intradermal
  • Intravenous
  • Subcutaneous

Neoantigen Targeted Therapies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neoantigen Targeted Therapies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
    • 5.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
    • 5.2.3. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
    • 5.2.4. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Neoantigen Targeted Therapies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Target Disease Indication
    • 6.2.2. By Neoantigens Type
    • 6.2.3. By Immunotherapy Type
    • 6.2.4. By Route of Administration
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neoantigen Targeted Therapies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Target Disease Indication
        • 6.3.1.2.2. By Neoantigens Type
        • 6.3.1.2.3. By Immunotherapy Type
        • 6.3.1.2.4. By Route of Administration
    • 6.3.2. Canada Neoantigen Targeted Therapies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Target Disease Indication
        • 6.3.2.2.2. By Neoantigens Type
        • 6.3.2.2.3. By Immunotherapy Type
        • 6.3.2.2.4. By Route of Administration
    • 6.3.3. Mexico Neoantigen Targeted Therapies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Target Disease Indication
        • 6.3.3.2.2. By Neoantigens Type
        • 6.3.3.2.3. By Immunotherapy Type
        • 6.3.3.2.4. By Route of Administration

7. Europe Neoantigen Targeted Therapies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Target Disease Indication
    • 7.2.2. By Neoantigens Type
    • 7.2.3. By Immunotherapy Type
    • 7.2.4. By Route of Administration
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neoantigen Targeted Therapies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Target Disease Indication
        • 7.3.1.2.2. By Neoantigens Type
        • 7.3.1.2.3. By Immunotherapy Type
        • 7.3.1.2.4. By Route of Administration
    • 7.3.2. France Neoantigen Targeted Therapies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Target Disease Indication
        • 7.3.2.2.2. By Neoantigens Type
        • 7.3.2.2.3. By Immunotherapy Type
        • 7.3.2.2.4. By Route of Administration
    • 7.3.3. United Kingdom Neoantigen Targeted Therapies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Target Disease Indication
        • 7.3.3.2.2. By Neoantigens Type
        • 7.3.3.2.3. By Immunotherapy Type
        • 7.3.3.2.4. By Route of Administration
    • 7.3.4. Italy Neoantigen Targeted Therapies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Target Disease Indication
        • 7.3.4.2.2. By Neoantigens Type
        • 7.3.4.2.3. By Immunotherapy Type
        • 7.3.4.2.4. By Route of Administration
    • 7.3.5. Spain Neoantigen Targeted Therapies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Target Disease Indication
        • 7.3.5.2.2. By Neoantigens Type
        • 7.3.5.2.3. By Immunotherapy Type
        • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Neoantigen Targeted Therapies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Target Disease Indication
    • 8.2.2. By Neoantigens Type
    • 8.2.3. By Immunotherapy Type
    • 8.2.4. By Route of Administration
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neoantigen Targeted Therapies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Target Disease Indication
        • 8.3.1.2.2. By Neoantigens Type
        • 8.3.1.2.3. By Immunotherapy Type
        • 8.3.1.2.4. By Route of Administration
    • 8.3.2. India Neoantigen Targeted Therapies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Target Disease Indication
        • 8.3.2.2.2. By Neoantigens Type
        • 8.3.2.2.3. By Immunotherapy Type
        • 8.3.2.2.4. By Route of Administration
    • 8.3.3. Japan Neoantigen Targeted Therapies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Target Disease Indication
        • 8.3.3.2.2. By Neoantigens Type
        • 8.3.3.2.3. By Immunotherapy Type
        • 8.3.3.2.4. By Route of Administration
    • 8.3.4. South Korea Neoantigen Targeted Therapies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Target Disease Indication
        • 8.3.4.2.2. By Neoantigens Type
        • 8.3.4.2.3. By Immunotherapy Type
        • 8.3.4.2.4. By Route of Administration
    • 8.3.5. Australia Neoantigen Targeted Therapies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Target Disease Indication
        • 8.3.5.2.2. By Neoantigens Type
        • 8.3.5.2.3. By Immunotherapy Type
        • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Neoantigen Targeted Therapies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Target Disease Indication
    • 9.2.2. By Neoantigens Type
    • 9.2.3. By Immunotherapy Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Target Disease Indication
        • 9.3.1.2.2. By Neoantigens Type
        • 9.3.1.2.3. By Immunotherapy Type
        • 9.3.1.2.4. By Route of Administration
    • 9.3.2. UAE Neoantigen Targeted Therapies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Target Disease Indication
        • 9.3.2.2.2. By Neoantigens Type
        • 9.3.2.2.3. By Immunotherapy Type
        • 9.3.2.2.4. By Route of Administration
    • 9.3.3. South Africa Neoantigen Targeted Therapies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Target Disease Indication
        • 9.3.3.2.2. By Neoantigens Type
        • 9.3.3.2.3. By Immunotherapy Type
        • 9.3.3.2.4. By Route of Administration

10. South America Neoantigen Targeted Therapies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Target Disease Indication
    • 10.2.2. By Neoantigens Type
    • 10.2.3. By Immunotherapy Type
    • 10.2.4. By Route of Administration
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Target Disease Indication
        • 10.3.1.2.2. By Neoantigens Type
        • 10.3.1.2.3. By Immunotherapy Type
        • 10.3.1.2.4. By Route of Administration
    • 10.3.2. Colombia Neoantigen Targeted Therapies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Target Disease Indication
        • 10.3.2.2.2. By Neoantigens Type
        • 10.3.2.2.3. By Immunotherapy Type
        • 10.3.2.2.4. By Route of Administration
    • 10.3.3. Argentina Neoantigen Targeted Therapies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Target Disease Indication
        • 10.3.3.2.2. By Neoantigens Type
        • 10.3.3.2.3. By Immunotherapy Type
        • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neoantigen Targeted Therapies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. BioNtech SE
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gritstone Bio, Inc.
  • 15.3. Genocea Biosciences Inc.
  • 15.4. Moderna Inc.
  • 15.5. Agenus Inc.
  • 15.6. Immatics NV
  • 15.7. Advaxis Inc
  • 15.8. Precision Biologics
  • 15.9. Gilead Sciences, Inc.
  • 15.10. Cellular Biomedicine Group Inc.
  • 15.11. Achillies Therapeutics Plc.
  • 15.12. Merck & Co Inc.

16. Strategic Recommendations

17. About Us & Disclaimer